Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Background Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear. Methods Two-dimensional and M-mode echocardiograms were recorded at baseline in 853 u...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2002-12, Vol.144 (6), p.1057-1064
Main Authors: Wachtell, Kristian, Dahlöf, Björn, Rokkedal, Jens, Papademetriou, Vasilious, Nieminen, Markku S., Smith, Gunnar, Gerdts, Eva, Boman, Kurt, Bella, Jonathan N., Devereux, Richard B.
Format: Article
Language:English
Subjects:
Aged
Antihypertensive agents
Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Atenolol - pharmacology
Atenolol - therapeutic use
Biological and medical sciences
Blood pressure
Body mass index
Cardiovascular system
Drug therapy
Female
Geometry
Heart attacks
Heart rate
Humans
Hypertension
Hypertension - complications
Hypertension - drug therapy
Hypertrophy, Left Ventricular - complications
Hypertrophy, Left Ventricular - diagnostic imaging
Losartan - pharmacology
Losartan - therapeutic use
Male
Medical sciences
Middle Aged
Mortality
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Regression analysis
Risk assessment
Statistical analysis
Stroke
Studies
Ultrasonic imaging
Ultrasonography
Variables
Ventricular Function, Left - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear. Methods Two-dimensional and M-mode echocardiograms were recorded at baseline in 853 unmedicated patients with stage II to III hypertension and LV hypertrophy determined by electrocardiography (Cornell voltage duration ≥2440 mV × ms or modified Sokolow-Lyon criteria: SV1 + RV5/RV6 >38 mV) after 14 days of placebo treatment. Follow-up echocardiography was done after 1 year of blinded treatment with either losartan or atenolol, in some cases supplemented with thiazide and calcium antagonist to reach target a BP of 140/90 mm Hg. Results Baseline systolic/diastolic BP were reduced from 174 ± 20/95 ± 11 to 151 ± 19/84 ± 11 mm Hg. LV mass was reduced from 234 ± 56 to 207 ± 51 g and relative wall thickness from 0.41 ± 0.07 to 0.38 ± 0.06 (all P
ISSN:0002-8703
1097-6744
DOI:10.1067/mhj.2002.126113